articleNature MedicineJan 1, 2022GREEN OA

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

TPThomas PowlesKYKobe YuenSGSilke GillessenEEEdward E. KadelDEDana E. Rathkopf

Queen Mary University of London · Institute of Oncology Research · +18 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

240
total citations
FWCI
33.25
Percentile
100%
References
60
Citations per year

Authors

20

Topics & keywords

Topics
Keywords
  • Enzalutamide
  • Prostate cancer
  • Medicine
  • Atezolizumab
  • Oncology
  • Internal medicine
  • Hazard ratio
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding